Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects.

Søgaard U, Michalow J, Butler B, Lund Laursen A, Ingersen SH, Skrumsager BK, Rafaelsen OJ.

Int Clin Psychopharmacol. 1990 Oct;5(4):237-51.

PMID:
2150527
2.

Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.

Farré M, Roset PN, Llorente M, Márquez M, Albet C, Pérez JA, Herrero E, Ortíz JA.

Methods Find Exp Clin Pharmacol. 1997 Jun;19(5):343-50.

PMID:
9379783
3.

Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.

Barbhaiya RH, Marathe PH, Greene DS, Mayol RF, Shukla UA, Gammans RR, Pittman KA, Robinson D.

J Clin Pharmacol. 1995 Oct;35(10):974-84.

PMID:
8568015
4.

Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.

Moore KH, Cass LM, Dallow N, Hardman TC, Jones A, Boyce M, Prince WT.

Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):805-11.

PMID:
11294370
5.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
6.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580
7.

Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men.

Kleinbloesem CH, Jaquet-Müller F, al-Hamdan Y, Baldauf C, Gisclon L, Wesnes K, Curtin CR, Stubbs RJ, Walker SA, Brunner-Ferber F.

Clin Pharmacol Ther. 1996 Jun;59(6):675-85.

PMID:
8681493
8.

Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.

O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP.

Clin Ther. 2007 Aug;29(8):1692-705.

PMID:
17919550
10.
11.

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.

Lim KS, Kim JR, Choi YJ, Shin KH, Kim KP, Hong JH, Cho JY, Shin HS, Yu KS, Shin SG, Kwon OH, Hwang DM, Kim JA, Jang IJ.

Clin Ther. 2008 Oct;30(10):1817-30. doi: 10.1016/j.clinthera.2008.10.013.

PMID:
19014837
12.

Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.

Algorta J, Pena MA, Alvarez A, Maraschiello C, Maruhn D, Windisch M, Mucke HA.

Int J Clin Pharmacol Ther. 2009 Jul;47(7):483-90.

PMID:
19640356
13.

Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects.

Mant T, Jurcevic S, Szakacs C, Adams L, Boland J, Hewitt LA.

Clin Ther. 2008 Jan;30(1):131-42. doi: 10.1016/j.clinthera.2008.01.017.

PMID:
18343249
14.

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A.

Clin Ther. 2008 Mar;30(3):499-512. doi: 10.1016/j.clinthera.2008.03.004.

PMID:
18405788
15.

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.

Matsushima N, Jakubowski JA, Asai F, Naganuma H, Brandt JT, Hirota T, Freestone S, Winters KJ.

Platelets. 2006 Jun;17(4):218-26.

PMID:
16769599
16.

Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.

Tarral A, Dostert P, Guillevic Y, Fabbri L, Rondelli I, Mariotti F, Imbimbo BP.

J Clin Pharmacol. 2003 Aug;43(8):901-11.

PMID:
12953347
17.

Nonlinear multiple-dose pharmacokinetics of the dopamine reuptake inhibitor vanoxerine.

Ingwersen SH, Snel S, Mant TG, Edwards D.

J Pharm Sci. 1993 Nov;82(11):1164-6.

PMID:
8289134
18.
19.
20.

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.

Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, Williams RR, Fowler CL, Cheung WK, Chow AT.

Antimicrob Agents Chemother. 1997 Oct;41(10):2256-60.

Supplemental Content

Support Center